U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206758) titled 'Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia' on Sept. 26.
Brief Summary: Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Intervention:
DRUG: SHR-2173 Injection
SHR-2173 injection treatment
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....